The proportion of participants who seroconverted ( i.e. had 4-folds or higher rise in reciprocal titre ) in the vaccine group were 65.9 % ( 95 % CI : 50.1 % -79.5 % ) at both 7 days ( i.e. after 1st dose ) and 21 days ( i.e. after 2nd dose ) .